Company Overview
Zentek Ltd., together with its subsidiaries, engages in the research and development of graphene and related nanomaterials in Canada. It develops graphene-based coatings under the ZenGUARD brand; graphene-enhanced intumescent gel under the ZenFire brand; carbon-based copolymeric icephobic coating under the ZenICE brand, and graphene-enhanced anti-corrosion coating under the ZenArmor brand. In addition, the company owns a 100% interest in the Albany graphite project located in Northern Ontario, Canada. The company was formerly known as ZEN Graphene Solutions Ltd. and changed its name to Zentek Ltd. in October 2021. Zentek Ltd. was incorporated in 2008 and is headquartered in Guelph, Canada.
Why Investors Should Care
Net profit has compounded at 10.7% per year over the last five years.
Revenue has grown at a 31.6% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.20.
Recent Developments
- Mar 2026 Revenue of $166.05K (-81.0% YoY); net profit $-9.77M.
- Trailing 12 Months Year-on-year growth — revenue -95.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 31.6%, profit CAGR 10.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 31.60% |
| 1 Year: | -95.50% |
Compounded Profit Growth
| 5 Years: | 10.74% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -17.07% |
| 6 Months: | -8.11% |
| 3 Months: | +58.14% |
| 1 Month: | +44.68% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)71.68 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 31.6% over 5 years.
- Profit CAGR of 10.7% over 5 years.
CONS
- Trading 35.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ZTEK Zentek Ltd. | 0.68 | -11.33 | $86.10M | 0.00% | -82.32% | -79.57% | 31.60% | 10.74% |
| 2 | LLY Eli Lilly and Company SPX | 1,148.84 | 40.85 | $1.02T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 256.35 | 29.74 | $617.09B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 250.94 | 122.41 | $443.36B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 414.40 | 31.23 | $376.34B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 130.20 | 36.68 | $321.57B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 169.64 | 26.30 | $263.09B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 574.30 | 31.54 | $213.42B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 385.16 | 26.78 | $207.87B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 813.60K | 57.80K | 6.20K | 65.28K | 36.77K |
| Cost of Revenue | - | 267.50K | 30.60K | 3.23K | 90.19K | 1.71M |
| Gross Profit | - | 546.09K | 27.20K | 2.98K | -24.91K | -1.68M |
| Operating Expenses | - | 2.91M | 1.83M | 2.33M | 2.36M | 1.74M |
| Operating Income | - | -2.10M | -1.80M | -2.32M | -2.39M | -3.42M |
| EBITDA | - | -1.88M | -1.17M | -2.19M | -2.29M | -3.33M |
| Interest Expense | - | -181.42K | 61.14K | 64.36K | 66.18K | 65.36K |
| Pretax Income | - | -1.84M | -1.36M | -2.39M | -2.49M | -3.53M |
| Tax Provision | 0 | 0 | - | - | - | - |
| Net Income | - | -1.84M | -1.36M | -2.39M | -2.49M | -3.53M |
| Diluted EPS | -0.02 | - | -0.01 | -0.02 | -0.02 | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 72.86K | 29.82K | 872.50K | 166.05K |
| Cost of Revenue | - | 853.34K | 331.08K | 644.61K | 1.84M |
| Gross Profit | - | -780.48K | -301.26K | 227.88K | -1.67M |
| Operating Expenses | - | 14.73M | 12.01M | 9.83M | 8.26M |
| Operating Income | - | -14.65M | -11.98M | -9.60M | -9.93M |
| EBITDA | - | -13.75M | -11.08M | -9.35M | -8.98M |
| Interest Expense | - | 120.62K | 107.37K | 91.32K | 257.04K |
| Pretax Income | - | -14.41M | -11.80M | -10.04M | -9.77M |
| Tax Provision | - | 0 | -99.78K | 0 | - |
| Net Income | - | -14.41M | -11.70M | -10.04M | -9.77M |
| Diluted EPS | - | -0.14 | -0.12 | -0.10 | -0.09 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 33.29M | 22.59M | 18.40M | 15.09M |
| Current Assets | - | 17.95M | 6.25M | 4.37M | 2.28M |
| Cash & Equivalents | - | 10.36M | 3.52M | 121.48K | 1.30M |
| Inventory | - | 2.85M | 1.42M | 887.51K | 417.55K |
| Receivables | - | 6.46K | 1.44K | 806.35K | 18.68K |
| Total Liabilities | - | 2.90M | 2.41M | 3.65M | 5.28M |
| Current Liabilities | - | 2.42M | 1.82M | 3.49M | 3.53M |
| Long Term Debt | 998.07K | - | 259.11K | - | 1.75M |
| Total Debt | - | 1.61M | 1.24M | 680.47K | 1.91M |
| Total Equity | - | 30.38M | 20.17M | 14.75M | 9.80M |
| Shares Outstanding | - | 99.53M | 100.82M | 104.39M | 107.79M |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -12.96M | -8.05M | -6.28M | -5.07M |
| Investing Cash Flow | - | -2.31M | 1.88M | 358.65K | 1.67M |
| Financing Cash Flow | - | -1.05M | -665.47K | 2.52M | 4.58M |
| Capital Expenditure | - | -2.27M | -591.96K | -184.61K | -701.86K |
| Free Cash Flow | - | -15.23M | -8.64M | -6.47M | -5.77M |
| Net Change in Cash | - | -16.32M | -6.84M | -3.40M | 1.18M |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | -1,071.3% | -1,010.4% | 26.1% | -1,007.5% |
| Operating Margin % | - | -20,112.5% | -40,174.8% | -1,100.4% | -5,981.2% |
| Net Margin % | - | -19,784.9% | -39,254.1% | -1,150.7% | -5,882.6% |
| ROE % | - | -47.4% | -58.0% | -68.1% | -99.7% |
| ROCE % | - | -47.5% | -57.7% | -64.4% | -86.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Scotia Capital Inc. | 0.67% | 845.66K | $575.05K |
| 2 | TD Waterhouse Canada Inc. | 0.22% | 281.68K | $191.54K |
| 3 | Royal Bank of Canada | 0.21% | 261.67K | $177.94K |
| 4 | SignatureFD, LLC | 0.10% | 125.00K | $85.00K |
| 5 | Citadel Advisors Llc | 0.09% | 113.68K | $77.30K |
| 6 | CIBC World Market, Inc. | 0.07% | 89.88K | $61.12K |
| 7 | Bcv Asset Management Inc. | 0.06% | 70.60K | $48.01K |
| 8 | Bank of Montreal /CAN/ | 0.05% | 60.89K | $41.41K |
| 9 | Geode Capital Management, LLC | 0.04% | 53.85K | $36.62K |
| 10 | Morgan Stanley | 0.04% | 51.94K | $35.32K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ZTEK
ZTEK — Frequently Asked Questions
What is the current share price of Zentek Ltd. (ZTEK)?
As of 2026-08-02 19:16 PDT, Zentek Ltd. (ZTEK) trades at $0.68 on NasdaqCM. Its 52-week range is $0.37 to $1.06.
What is the market capitalisation of ZTEK?
Zentek Ltd. (ZTEK) has a market capitalisation of $86.10M on NasdaqCM.
What is the P/E ratio of ZTEK?
ZTEK trades at a trailing price-to-earnings (P/E) ratio of -11.33. The industry average P/E is 27.41. Its price-to-book (P/B) ratio is 10.49.
What is the return on equity (ROE) of ZTEK?
ZTEK has a return on equity (ROE) of -79.57%. Its return on capital employed (ROCE) is -82.32%.
Is ZTEK a good stock to buy?
This page provides a data-driven analysis of Zentek Ltd. (ZTEK), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.